SWOG
- Country
- đēđ¸United States
- Ownership
- Private, Subsidiary
- Established
- 1956-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.swog.org
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
- Conditions
- Plasma Cell NeoplasmMultiple Myeloma
- Interventions
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 198
- Registration Number
- NCT00064038
- Locations
- đēđ¸
William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
đēđ¸Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00026520
- Locations
- đēđ¸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
đēđ¸CCOP - Atlanta Regional, Atlanta, Georgia, United States
đēđ¸MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
- Conditions
- Lung Cancer
- Interventions
- Procedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 46
- Registration Number
- NCT00062439
- Locations
- đēđ¸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
đēđ¸Holland Community Hospital, Holland, Michigan, United States
đēđ¸Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2003-06-02
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00006484
- Locations
- đēđ¸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
đēđ¸CCOP - Central Illinois, Decatur, Illinois, United States
đēđ¸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
- Conditions
- Cervical Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00057928
- Locations
- đēđ¸
Arizona Cancer Center, Tucson, Arizona, United States
đēđ¸Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States
đēđ¸Mayo Clinic, Jacksonville, Florida, United States
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
- Conditions
- Kidney Cancer
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 43
- Registration Number
- NCT00058318
S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)
- Conditions
- Penile Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1
- Registration Number
- NCT00058448
- Locations
- đēđ¸
Kalispell Regional Medical Center, Kalispell, Montana, United States
đēđ¸Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
đēđ¸Rose Ramer Cancer Clinic at Anderson Area Medical Center, Anderson, South Carolina, United States
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
- Conditions
- Urethral CancerBladder Cancer
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 7
- Registration Number
- NCT00055835
- Locations
- đēđ¸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
đēđ¸MBCCOP - Gulf Coast, Mobile, Alabama, United States
đēđ¸CCOP - Columbus, Columbus, Ohio, United States
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00054054
- Locations
- đēđ¸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
đēđ¸CCOP - Atlanta Regional, Atlanta, Georgia, United States
đēđ¸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 2
- Registration Number
- NCT00053833
- Locations
- đēđ¸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
đēđ¸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
đēđ¸MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States